Asia Pacific Anti-Viral Therapies Market Share and Forecast by 2027
Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027Asia Pacific Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Country
- Report Date : Sep 2020
- Report Code : TIPRE00014173
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 117
The Asia Pacific anti-viral therapies market is expected to reach US$ 16,118.52 million by 2027 from US$ 8,135.93 million in 2019; it is estimated to grow at a CAGR of 9.0% from 2020 to 2027.
Increasing R&D expenditures in pharmaceutical companies and rising government support for research activities and clinical trials are the key factors driving the growth of the Asia Pacific Anti-Viral Therapies market in this region. However, high cost of drug development is a key factor hindering the market growth in Asia Pacific.
Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.
Asia is emerging as a powerhouse of pharmaceutical R&D on the back of vast patient population, quality data, lower costs, and skilled manpower availability. For instance, AstraZeneca has announced its plans to spend US$ 100 million in expanding its research operations in China, with the main focus on a program to better understand Chinese patients’ genetic profile to develop new therapies for the Chinese population. According to experts, such costs are reduced to half when clinical research activities are outsourced from low-cost economies such as India. Other Asian countries such as Malaysia, South Korea, and Taiwan are also attracting a number of international pharma companies to outsource their R&D activities. The government of Taiwan is planning to spend US$ 4.48 billion on biomedical research. Regulatory environments in these countries are conducive to clinical trials. Vast patient population, low procedure costs, huge R&D workforce, and favorable regulatory environment are the main factors driving the transformation of Asia into the hub of R&D activities.
Countries in Asia Pacific are experiencing the rise in number of COVID-19 cases. A research team from Beijing, China has successfully tested a drug on animal that would reduce the recovery time for COVID-19 patients and confer short-term immunity to the virus. Further, the National Medical Products Administration of China has approved the anti-viral drug Favilavir to treat COVID-19 patients. Additionally, China has approved to assess a third vaccine candidate against COVID-19.
Rest of Asia Pacific Anti-Viral Therapies Market, Revenue and Forecast to 2027 (US$ Million)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
ASIA PACIFIC ANTI-VIRAL THERAPIES MARKET SEGMENTATION
By Type
- Branded Drugs
- Generic Drugs
By Mechanism of Action
- Nucleotide Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Application
- HIV
- Hepatitis
- Virus Influenza
- Herpes
- Others
By Country
- China
- Japan
- India
- South Korea
- Australia
Company Profiles
- Aurobindo Pharma Ltd
- AbbVie Inc
- GlaxoSmithKline plc
- AstraZeneca
- F. HOFFMANN-LA ROCHE LTD
Asia Pacific Anti-Viral Therapies Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 8,135.93 Million |
| Market Size by 2027 | US$ 16,118.52 Million |
| Global CAGR (2020 - 2027) | 9.0% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Asia-Pacific
|
| Market leaders and key company profiles |
Market Research & Consulting
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
The List of Companies - Asia Pacific Anti-Viral Therapies Market
- Aurobindo Pharma Ltd
- AbbVie Inc.
- GlaxoSmithKline plc
- AstraZeneca
- F. HOFFMANN-LA ROCHE LTD
Get Free Sample For